文献速递药物不良反应与药物警戒抗栓抗凝管理

阿哌沙班可能诱发的白细胞碎裂性血管炎

Possible apixaban-induced leukocytoclastic vasculitis.
PubMed 文献 · Am J Health Syst Pharm · 2020-01-01

本文报告一例74岁女性深静脉血栓患者,在阿哌沙班治疗第23天出现皮疹并经皮肤科会诊诊断为白细胞碎裂性血管炎(LCV)。停用阿哌沙班并换用利伐沙班后,LCV逐步改善,DVT治疗顺利完成且未再复发。

要点

  • 阿哌沙班治疗期间出现皮疹需警惕LCV可能
  • 疑诊LCV时应及时停用可疑药物并请皮肤科会诊
  • 换用利伐沙班后LCV缓解且未复发,提示同类药物中可考虑替代

核心结论

  • 一例女性DVT患者服用阿哌沙班期间发生LCV,换用利伐沙班后LCV缓解并完成DVT治疗,未再复发。

研究设计与样本

  • 病例报告:74岁白人女性,体重102 kg,因左下肢DVT接受阿哌沙班治疗。

主要发现

  • 阿哌沙班用法为10 mg每日两次用7天,随后5 mg每日两次用3个月。
  • 治疗1周随访时双下肢出现小片红疹,第23天皮疹进展,皮肤科会诊诊断为LCV。
  • 第24天停用阿哌沙班,换用利伐沙班20 mg每日一次完成剩余DVT治疗。
  • 第73天LCV逐步改善,仅留微量瘀点;利伐沙班用至DVT治疗结束,未再报告LCV。

临床怎么用

  • 阿哌沙班治疗期间出现皮疹应评估LCV可能,必要时请皮肤科会诊。
  • 疑诊阿哌沙班相关LCV时停用该药,可考虑换用利伐沙班等替代抗凝药完成DVT治疗。

局限性

  • 本文为单例病例报告,无法确立阿哌沙班与LCV的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The development of leukocytoclastic vasculitis (LCV) during apixaban therapy in a female patient being treated for deep vein thrombosis (DVT) is reported. SUMMARY: A 74-year-old Caucasian woman weighing 102 kg presented to a walk-in clinic with complaints of mild pain and swelling in her left leg for 2 weeks. She was diagnosed as having left lower-extremity DVT. The direct oral anticoagulant (DOAC) apixaban (10 mg twice daily for 7 days, then 5 mg twice daily for 3 months) was prescribed. At 1-week follow-up the patient stated that her DVT symptoms were slowly improving and reported that small areas of red rash had appeared bilaterally on her lower extremities. On day 23 of apixaban therapy, the patient presented to a walk-in clinic with a complaint that the rash had progressively worsened. The rash was diagnosed as LCV by dermatology consult. On day 24 of therapy, apixaban use was discontinued and the patient was initiated on rivaroxaban (20 mg daily) for the remainder of DVT treatment. LCV was found to be progressively improving on day 73, with trace petechiae. Rivaroxaban was used through the end of DVT treatment without further reports of LCV. CONCLUSION: A female patient who developed LCV while taking apixaban for treatment of DVT was successfully transitioned to rivaroxaban therapy, leading to resolution of LCV and successful completion of DVT treatment without recurrence of LCV.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Daul B, Petersen G, Butler J, et al. Possible apixaban-induced leukocytoclastic vasculitis. Am J Health Syst Pharm. 2020. PMID: 32789435. doi:10.1093/ajhp/zxaa182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。